Monuvir Capsule 200 mg

Monuvir Capsule, containing Molnupiravir 200 mg, is an antiviral medication manufactured by Eskayef Pharmaceuticals Ltd. It is prescribed for mild-to-moderate COVID-19 in high-risk adults to prevent severe illness. Priced at ৳50 per capsule (strip: ৳500 for 10 capsules), it offers an emergency-authorized oral therapy to reduce hospitalization risks.

This capsule formulation disrupts SARS-CoV-2 replication by introducing RNA mutations, causing lethal errors in viral RNA. Patients take 4 capsules every 12 hours for 5 days. Avoid use in under-18s or pregnant/breastfeeding individuals due to potential fetal harm and unknown milk transfer risks.

Common side effects include diarrhea, nausea, dizziness, and headache. Store below 25°C, away from moisture. While no major drug interactions are reported, consult doctors before combining with other therapies. Monuvir is part of the anti-viral drugs class, with alternatives like Lagevrio.

Adults: 800 mg (four 200 mg capsules) every 12 hours for 5 days. Not approved for patients <18 years. No dose adjustment recommended for renal/hepatic impairment. Swallow capsules whole with water. Initiate treatment within 5 days of symptom onset for optimal efficacy.

Common side effects include diarrhoea, nausea, feeling dizzy, headache.

Pregnancy Category: Not recommended. Contraindicated due to fetal toxicity in animal studies. Advise contraception during treatment + 4 days post-dose. Breastfeeding contraindicated – excretion in milk unknown.

Precautions: Use caution in immunocompromised patients (e.g., HIV). Monitor for hyperuricemia in predisposed individuals. No routine lab monitoring required. Report any neurological symptoms immediately.

Pediatric: Contraindicated <18 years. Geriatric: No dose adjustment unless significant renal impairment. Hepatic/Renal: No changes needed for mild-moderate impairment. Severe cases: Use clinical judgment.